Targeting protein kinase C in mantle cell lymphoma |
| |
| Authors: | Hilka Rauert‐Wunderlich Martina Rudelius German Ott Andreas Rosenwald |
| |
| Affiliation: | 1. Institute of Pathology, University of Würzburg and Comprehensive Cancer Center (CCC) Mainfranken, Würzburg, Germany;2. Department of Clinical Pathology, Robert‐Bosch‐Krankenhaus, Stuttgart, Germany;3. Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology, Stuttgart, Germany |
| |
| Abstract: | Although targeting the Bruton tyrosine kinase (BTK) with ibrutinib has changed lymphoma treatment, patients with mantle cell lymphoma (MCL) remain incurable. In this study, we characterized a broad range of MCL cell lines and primary MCL cells with respect to the response to the BTK inhibitor, ibrutinib, and compared it with the response to the protein kinase C (PKC) inhibitor, sotrastaurin. At clinically relevant concentrations, each drug induced potent cell death only in the REC‐1 cell line, which was accompanied by robust inhibition of AKT and ERK1/ERK2 (ERK1/2, also termed MAPK3/MAPK1) phosphorylation. In sensitive REC‐1 cells, the drug‐mediated impaired phosphorylation was obvious on the levels of B‐cell receptor‐induced and basal phosphorylation. Similar results were obtained in primary MCL cells with ibrutinib and in a subset with sotrastaurin. The various drug‐resistant MCL cell lines showed very distinct responses in terms of basal AKT and ERK1/2 phosphorylation. Interestingly, targeting PKC and BTK at the same time led to ibrutinib‐mediated rescue of a weak sotrastaurin‐induced apoptosis in MINO cells. Additional targeting of AKT sensitized MINO cells to inhibitor‐mediated cytotoxicity. In summary, MCL cells are heterogeneous in their response to BTK or PKC inhibition, indicating the need for even more individualized targeted treatment approaches in subsets of MCL patients. |
| |
| Keywords: | sotrastaurin ibrutinib Bruton tyrosine kinase mantle cell lymphoma B‐cell receptor signalling |
|
|
